Dr. Reddy’s
Laboratories announced that it has launched Zafirlukast tablets (10 mg and 20
mg), a bioequivalent generic version of Accolate® in the US market.
The U.S. District Court of New Jersey granted Dr. Reddy’s motion for summary judgment of non-infringement against AstraZeneca clearing the way for the launch of the product. Subsequently, the Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Zafirlukast tablets on November 18, 2010. Zafirlukast had total U.S. sales of approximately $50 million for the twelve months ending August 31, 2010 according to IMS Health.
Dr. Reddy’s Zafirlukast tablets are available in bottles of 60 counts in 10mg and 20 mg strengths.
The U.S. District Court of New Jersey granted Dr. Reddy’s motion for summary judgment of non-infringement against AstraZeneca clearing the way for the launch of the product. Subsequently, the Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Zafirlukast tablets on November 18, 2010. Zafirlukast had total U.S. sales of approximately $50 million for the twelve months ending August 31, 2010 according to IMS Health.
Dr. Reddy’s Zafirlukast tablets are available in bottles of 60 counts in 10mg and 20 mg strengths.
No comments:
Post a Comment